We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cell Lines Available for Research

By Biotechdaily staff writers
Posted on 23 Oct 2005
Nine cell lines are available to commercial and academic researchers worldwide who are seeking a cure for lymphoma, leukemia, pancreatic cancer, or macroglobulinema.

The cell lines were developed by researchers at the Barbara Ann Karmanos Cancer Institute of Wayne State University (Detroit, MI, USA) and are being distributed by Asterand, Inc. More...
(Detroit, MI, USA; www.asterand.com). Asterand also markets breast cancer cell lines under license from the University of Michigan (Ann Arbor, USA) and prostate cancer lines from Onyvax (London, UK). The company acquires donated samples from a world-wide network of collaborating hospitals and clinics.

Following are the cell lines available: Waldenstrom's macroglobulinema, follicular small cleaved cell lymphoma, diffuse large cell lymphoma (chemo-resistant), acute lymphoblastic leukemia (early stage), acute myeloid leukemia, pancreatic cancer, diffuse large cell lymphoma, Burkitt's lymphoma, and nodal histiocytic lymphoma (intermediate grade).

"These cell lines are very good model systems for diseases they are derived from,” said Dr. James Eliason, chief scientific officer of Asterand. "They have been studied extensively by researchers at Wayne State University and elsewhere, which is evident by the fact that there are over 50 publications related to them. In addition to common cancers, these cell lines are great resources for studying rare cancers such as Burkitt's lymphoma, which affects children and young people, aged 12-30, or pancreatic cancer, which is probably one of the most difficult cancers to detect.”




Related Links:
Asterand

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Steam Sterilizer
Hi Vac II Line
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.